Ruihan Zhang^1,2, Junhao Yang¹, Chunxiao Chen^1,*

Molecular & Cellular Biomechanics, Vol.15, No.3, pp. 177-187, 2018, DOI:10.3970/mcb.2018.04292

Abstract The proportion of cells staining for the nuclear antigen Ki-67 is an important predictive indicator for assessment of tumor cell proliferation and growth in routine pathological investigation. Instead of traditional scoring methods based on the experience of a trained laboratory scientist, deep learning approach can be automatically used to analyze the expression of Ki-67 as well. Deep learning based on convolutional neural networks (CNN) for image classification and single shot multibox detector (SSD) for object detection are used to investigate the expression of Ki-67 for assessment of biopsies from patients with breast cancer in this More >

Guanling Chen¹, Zhaoze Guo¹, Minfeng Liu, Guangyu Yao, Jianyu Dong, Jingyun Guo, Changsheng Ye

Oncology Research, Vol.25, No.9, pp. 1567-1578, 2017, DOI:10.3727/096504017X14897173032733

Abstract Capecitabine has consistently demonstrated high efficacy and acceptable tolerability in salvage chemotherapy for advanced breast cancer. However, there remains no consensus on its role in adjuvant chemotherapy for early breast cancer (EBC). To estimate the value of capecitabine-based combination adjuvant treatment in EBC, eight randomized controlled trials with 14,072 participants were analyzed. The efficacy and safety outcomes included disease-free survival (DFS), overall survival (OS), relapse, breast cancer-specific survival (BCSS), and grades 3–5 adverse events. Capecitabine-based combination adjuvant chemotherapy demonstrated a 16% increase in BCSS (HR = 0.84, 95% CI = 0.71–0.98, p = 0.03) in the… More >

Shuke Ge^*, Dan Wang^†, Qinglong Kong^‡, Wei Gao^*, Jiayi Sun^*

Oncology Research, Vol.25, No.8, pp. 1363-1371, 2017, DOI:10.3727/096504017X14878536973557

Abstract miR-152, as a tumor suppressor, has been reported to be downregulated in a number of cancer cell lines and tumor tissues, including breast cancer. This study aimed to investigate the role of miR-152 in human breast cancer and its underlying mechanisms. Human breast cancer cell line HCC1806 was transfected with hsa-miR- 152-3p mimic, inhibitor, or scrambled negative controls. The efficiency of miR-152-3p transfection was evaluated by quantitative real-time PCR, and the effects on cell viability and apoptosis as well as on the PI3K/AKT signaling pathway were investigated by MTT assay, flow cytometry, and Western blot… More >

Maitham A. Khajah, Princy M. Mathew, Yunus A. Luqmani

Oncology Research, Vol.25, No.8, pp. 1283-1295, 2017, DOI:10.3727/096504017X14883245308282

Abstract Current mainstream pharmacological options for the treatment of endocrine-resistant breast cancer have limitations in terms of their side effect profile and lack of discrimination between normal and cancer cells. In the current study, we assessed the responses of normal breast epithelial cells MCF10A, estrogen receptorpositive (ER+ ) MCF-7, and ER-silenced pII breast cancer cells to inhibitors (either individually or in combination) of downstream signaling molecules. The expression/activity of ERK1/2, p38 MAPK, and Akt was determined by Western blotting. Cell proliferation, motility, and invasion were determined using MTT, wound healing, and Matrigel assays, respectively. Morphological changes… More >

Valentina K. Todorova^*, Issam Makhoul^†, Ishwori Dhakal^‡, Jeanne Wei^§, Annjanette Stone^¶, Weleetka Carter^¶, Aaron Owen^*, V. Suzanne Klimberg^*

Oncology Research, Vol.25, No.8, pp. 1223-1229, 2017, DOI:10.3727/096504017X14876245096439

Abstract Doxorubicin (DOX) is a commonly used antineoplastic agent for the treatment of various malignancies, and its use is associated with unpredictable cardiotoxicity. Susceptibility to DOX cardiotoxicity is largely patient dependent, suggesting genetic predisposition. We have previously found that individual sensitivity to DOX cardiotoxicity was associated with differential expression of genes implicated in inflammatory response and immune trafficking, which was consistent with the increasing number of reports highlighting the important role of human leukocyte antigen (HLA) complex polymorphism in hypersensitivity to drug toxicity. This pilot study aimed to investigate DNA from patients treated with DOX-based chemotherapy… More >

Jiateng Zhong^*†, Haijun Wang^*, Jian Yu^‡, Jinghang Zhang^‡, Hui Wang^†§

Oncology Research, Vol.25, No.6, pp. 959-965, 2017, DOI:10.3727/096504016X14803482769179

Abstract Forkhead box L1 (FOXL1) is a member of the Forkhead box (FOX) superfamily and was reported to be dysregulated in various types of cancers. However, its expression pattern and underlying cellular function in breast cancer remain largely unexplored. Thus, the aim of this study was to detect FOXL1 expression in breast cancer and to analyze its role in the progression of breast cancer. Our results demonstrated that FOXL1 expression at both the mRNA and protein levels was downregulated in breast cancer tissues and cell lines. Ectopic FOXL1 suppressed breast cancer cell proliferation, migration, and invasion More >

Zhiling Zhang, Jiawei Wang, Runfang Gao, Xuan Yang, Yafen Zhang, Jie Li, Jing Zhang, Xingjuan Zhao, Chunfang Xi, Xiaoting Lu

Oncology Research, Vol.25, No.5, pp. 753-761, 2017, DOI:10.3727/096504016X14772342320617

Abstract Our study aimed to investigate whether microRNA-449 (miR-449) plays a key role in regulating the migration and invasion of breast cancer cells via targeting tumor protein D52 (TPD52). The results of the qRT-PCR and Western blotting showed that, in comparison with normal breast tissues and cells, miR-449 was significantly downregulated in breast cancer tissues and cells, while TPD52 was markedly upregulated. After transfection with an miR-449 inhibitor, suppression of miR-449 significantly promoted cell migration and invasion. Also, when miR-449 was overexpressed by transfection with miR-449 mimics, E-cadherin expression significantly increased, and the expression of N-cadherin More >

Gamal A. Elfar^*†, Mohamed A. Ebrahim^‡, Nehal M. Elsherbiny^*, Laila A. Eissa^*

Oncology Research, Vol.25, No.4, pp. 641-650, 2017, DOI:10.3727/096504016X14768398678750

Abstract Osteoprotegerin (OPG) is a robust antiresorptive molecule that acts as a decoy receptor for the receptor activator of nuclear factor kB ligand (RANKL), the mediator of osteoclastogenesis. This study was designed to explore the possible role of serum OPG and RANKL in detecting bone metastasis in breast cancer and its interaction with clinicopathologic parameters. Serum levels of RANKL and OPG were estimated in 44 metastatic and 36 nonmetastatic breast cancer patients using ELISA kits. Serum OPG levels were significantly reduced in patients with bone metastasis and correlated negatively with the number of bone lesions and… More >

Li Xianglei, Li Yanhua, Lu Hong

Oncology Research, Vol.25, No.4, pp. 579-585, 2017, DOI:10.3727/97818823455816X14760504645779

Abstract THIS ARTICLE WAS WITHDRAWN BY THE PUBLISHER IN NOVEMBER 2020 More >

Ying Liu^*†, Hui Lv^‡, Xiaoying Wu^*§, Jun Zhou^¶, Ying Shi^#, Jifang Wen^*†

Oncology Research, Vol.25, No.3, pp. 445-454, 2017, DOI:10.3727/096504016X14747368729786

Abstract Breast cancer is the leading cause of cancer deaths in females all over the world, mainly resulting from metastasis. Previous studies have revealed that repressor element-1 (RE-1) silencing transcription (REST) acted as a tumor suppressor in breast cancer. However, the mechanism by which REST is regulated remains unknown, and its role in the metastasis in breast cancer cells remains unclear. In the present study, we showed that the expression of REST was lower in breast cancer samples than that of adjacent samples by immunohistochemical analysis, which may be due to hypermethylation of the REST promoter.… More >